The University of Chicago Medical Center Cardiac Department Evaluates the VMS+ Complete Heart Analysis System

Tickers: XTSX:VPT, PINX:VPTDF
Tags: Heathcare, Technology

Toronto, Ontario / TheNewswire / November 5, 2018 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of Chicago Medical Center in Chicago, Illinois will be receiving the VMS+ complete heart analysis system.

Spearheaded by Dr. Roberto Lang, the VMS+ system will be installed and used for 3D volumetric analysis of the whole-heart. With the recent market clearance from the FDA, the University of Chicago will be one of the first sites to evaluate and publish on the performance of the VMS+ system vs MRI for all 4 cardiac chambers.

Dr. Roberto M. Lang is a Professor of Medicine and Director of the Non-invasive Cardiac Imaging Laboratory at the University of Chicago. He is an internationally renowned cardiologist and specialist in echocardiography, the study of heart function using sound waves. Dr. Lang uses his vast knowledge of cardiac imaging techniques to evaluate patients with a wide variety of heart conditions, including heart failure and valve disease. In addition, he has been named one of the top cardiologists in Chicago by Chicago magazine.

"We are very pleased to have the VMS+ system installed in a very busy clinical environment such as the Department of Medicine at the University of Chicago," commented Desmond Hirson, President of Ventripoint. "We believe that our product in the hands of the Non-invasive Cardiac Imaging Laboratory under the direction of Dr. Lang, will make a valuable difference to patient outcomes."

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI) to render 3D volumes for all four chambers of the heart providing clinicians with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

About the University of Chicago Medicine

The University of Chicago Department of Medicine is a leader in innovative, comprehensive patient care. Its cardiac and vascular experts have pioneered treatments and continue to make advancements in patient care. The Department of Medicine heart and vascular care program is one of the nation’s most comprehensive programs using robotic surgery for cardiovascular operations and has a nationally acclaimed program in bloodless cardiac surgery and cardiovascular imaging, using advanced diagnostics, including three-dimensional echocardiography.

About Ventripoint Diagnostics Ltd.

Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information, please contact:

Dr. George Adams, CEO, Telephone: (519) 803-6937

Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation’s most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2018 TheNewswire – All rights reserved.

TheNewswire.com – RSS (all)